Navigation Links
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Date:1/2/2014

SEATTLE, Jan. 2, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival, and is under development for the treatment of blood-related cancers. Tosedostat is currently being studied in the United States and European Union in investigator-sponsored and cooperative group-sponsored Phase 2 trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

"We are pleased that the FDA has responded favorably to the tosedostat clinical trial data provided and removed the partial clinical hold to allow further development of tosedostat in ongoing and future studies," said John Pagel, MD, PhD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor, Medical Oncology Division, University of Washington School of Medicine; and Principal Investigator in the tosedostat first-line AML/MDS trial.

About AML and MDS

Approximately 14,590 new cases of AML were expected to be diagnosed in the United States in 2013.1 As of January 2008 an estimated 30,993 people were living with (or were in remission from) AML.2 Although AML can occur at any age, adults aged 60 years and older are more likely to develop the disease than younger people. AML is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML may develop fr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... AUSTIN, Texas, Feb. 15, 2011 Luminex Corporation ... it has teamed with Partners HealthCare toward the ... assays.  This program will enable Partners HealthCare Center ... molecular diagnostic assays based on biomarkers discovered within ...
... SAN DIEGO and INGELHEIM, Germany, Feb. 15, 2011 ... expression through the Pfenex Expression Technology™ platform and ... and global leader in biopharmaceutical contract development and ... a strategic agreement. It provides Boehringer Ingelheim with ...
Cached Medicine Technology:Luminex and Partners HealthCare Announce Collaboration Agreement 2Luminex and Partners HealthCare Announce Collaboration Agreement 3Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 2Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the Use of Pfenex Expression Technology™ 3
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... URBANA, Ill. - In a country as wealthy as the ... in 12 seniors do not have access to adequate food ... are food insecure. , Recent research at the University ... Examination Survey (NHANES) revealed that the seniors who are dealing ... , "In 2011, 8.35 percent of Americans over age ...
(Date:4/23/2014)... of scientists led by a researcher from the Cancer ... University of Singapore has identified the cancer specific stem ... the possibility of developing new drugs for the treatment ... The research group, led by Dr Chan Shing Leng, ... first time that a cancer-specific variant of a cell ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... known as Ritalin, may prevent the depletion of self-control, ... a journal of the Association for Psychological Science. , ... or trying to focus attention on a boring textbook ... potential explanation for this difficulty: Exerting self-control for a ... self-control effectively on subsequent tasks. , "It is as ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2
... glucose control can lower the risk of cardiovascular disease in ... control on the blood sugar levels mean that for patients ... to the normal levels as possible. Conventionally this can be ... diet and exercise plan, and adjusting medication according to the ...
... and calcium can ward off an attack of premenstrual ... set of symptoms that affect a lot of women ... common symptoms of PMS are depression, feelings of aggression ... feel their social interactions and relationships are getting affected ...
... in a number of people// with pre-diabetic conditions for diabetes ... use its own insulin to control blood sugar. As this ... overcome insulin resistance and keep up to the need of ... of blood glucose existent in patients, but the levels are ...
... new revealation, researchers have shown that twisting the graft to ... and last longer. ,In using a graft to bypass ... also used when patients with renal problems have dialysis. This ... shunt have difficlties, as in the blood vessels, the blood ...
... tissues, which have been genetically altered to express skin ... will provide them with new insight in the oncogenic ... ,Melanoma is the deadliest form of skin cancer that ... ,The scientists from the Stanford University School of Medicine ...
... says that people with low birth weight may help ... and controlling their body weights. ,Diabetes affects the ... glucose and impaired function of the insulin that helps ... factors for diabetes are obesity, physical inactivity, genetic influence ...
Cached Medicine News:
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
These backbiters enable simple access to the anterior horn of the meniscus....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
Medicine Products: